Bluejay Diagnostics Announces Closing of $8.75 Million Underwritten Public Offering

Company Overview - Bluejay Diagnostics, Inc. is a medical diagnostics company focused on improving patient outcomes through its Symphony System, which provides rapid, near-patient testing for sepsis triage and disease progression monitoring [3]. Offering Details - The company announced the closing of a public offering with gross proceeds expected to be approximately $8.75 million, before deducting underwriting discounts and estimated expenses [9]. - The offering consisted of 5,368,098 Common Units or Prefunded Units, with each unit comprising one share of common stock or one pre-funded warrant, two Class C warrants, and one Class D warrant [9]. - The purchase price for each Common Unit was set at $1.63, while the Prefunded Unit was priced at $1.6299 [9]. Use of Proceeds - The net proceeds from the offering will be utilized to repay $2.3 million in outstanding debt, fund FDA approval-related activities, and support research and development, as well as general working capital needs [5]. Underwriting and Legal Counsel - Aegis Capital Corp. acted as the underwriter for the offering, while Hogan Lovells US LLP served as counsel to the company [6].